MicroPort® MedBot Attends CUA 2021 with MicroPort® Urocare

Nanjing, China, 1 November 2021 — Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) and MicroPort Urocare (Jiaxing) Co., Ltd. (MicroPort® Urocare) joined together at the 28th China Urological Association Congress (CUA 2021), held in Nanjing recently, to showcase various medical solutions and innovative products by MicroPort® for minimally invasive urological surgery. The Congress, which marks the 40th anniversary of the Urological Association of the Chinese Medical Association, attracted top urologists and scholars from across China.

MicroPort® MedBot presented its Toumai® Laparoscopic Surgery Robot (Toumai®) and the DFVision® 3D Electronic Laparoscope (DFVision®) to the participants at the Congress. Many urology experts visited the MicroPort® booth and tried out both products, with many acknowledging that as technology advances, surgical robots and other emerging technologies will enhance the precision, intelligence, safety, universality, and minimal invasiveness of urologic surgeries.

MicroPort® Urocare showcased the world’s first laminated stone interception device, as well as a number of other products including a disposable ureteroscope, an anti-reflux stent, and a nephrostomy balloon catheter. Numerous experts visited the booth and test-operated the disposable ureteroscope, recognizing the curvature and high-definition image quality.

As an innovator that provides a complete set of non-vascular interventional solutions, MicroPort® Urocare currently has 78 patent applications, 28 licenses, 3 PCTs, and more than 30 projects in development and pre-development. Of its 14 registered products on the market, 13 are in the category of urinary stone treatment, including products for guiding, dilation, access, direct vision, stone extraction and drainage.

Today, MicroPort® markets over 400 products developed by twelve business clusters, including cardiovascular intervention and structural heart disease, electrophysiology and cardiac rhythm management, orthopedics and soft tissue repair technology, cerebrovascular and neuromodulation science, surgical emergency and robotics, and urogynecology. At the Congress, MicroPort® presented its medical solutions and innovative R&D results in ‘interventional consumables and devices’ for urology. In the future, MicroPort® will continue to innovate and provide accessible and holistic total medical solutions for non-vascular interventions.

About MicroPort MedBot

MicroPort® MedBot is a subsidiary of MicroPort Scientific Corporation (00853.HK, MicroPort®). MicroPort® started its strategic development of medical robots in 2014 and has since been engaged in independent research and development of a range of surgical robots. By conducting cutting-edge research and industrial integration in the fields of robotics, intelligent control, sensing, and information to fulfill the pioneering development needs of minimally invasive surgery, MicroPort® MedBot is committed to providing innovative total solutions to prolong and reshape life with the help of medical robotics.

About MicroPort Urocare

MicroPort Urocare is a subsidiary of MicroPort Scientific Corporation (00853.HK, MicroPort®). MicroPort® Urocare is dedicated to the development, production and sales of diagnostic and treatment devices in the field of non-vascular intervention, covering various areas such as urology and gynecology, gastrointestinal interventions, and respiratory interventions.